Effects of pausing nerve stimulation therapy on heart and metabolism in sleep apnea
Tests how stopping nerve stimulation briefly affects heart and metabolism measures in obstructive sleep apnea.
Key facts
- Who runs it
- Columbia University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 5 Jan 2025
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- No HGNS therapy (HGNS-off)
- Record updated
- 10 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for English-speaking adults with obstructive sleep apnea who already use an implanted hypoglossal nerve stimulation (HGNS) device that works well for them. The study looks at heart and metabolism measures when HGNS is turned off for a short time.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Obstructive sleep apnea that improved with HGNS: at least a 50% drop in apnea-hypopnea index (AHI, breathing pauses per hour) to <20.
- Earlier treatment
- Must have used HGNS for at least 3 months, and for >20 hours/week in the past 4 weeks. Must have had no sleep apnea treatment for at least one month before HGNS was switched on, or a one-month untreated period after.
Main reasons for not taking part
- Long-term use of opiate medicines, illegal drugs, or alcohol dependency
- Pregnant or planning to become pregnant
- Shift workers, heavy machinery operators, or commercial drivers
- Severe daytime sleepiness (Epworth score >16), or car accidents or near misses from drowsy driving in the past year
- Serious heart, lung, liver, kidney, cancer or brain-degenerating disease, or an eating disorder in the last 5 years
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- English-speaking adults (18+ years) who have met surgical efficacy criteria with HGNS, as defined by at least a 50% reduction in apnea-hypopnea index (AHI) to <20 (with hypopneas defined by 4% oxyhemoglobin desaturations)
- Have been using HGNS therapy for at least 3 months and used HGNS for >20 hours/week during the past 4 weeks
- Were not using any OSA therapy for at least one month prior to HGNS activation or have had a one-month period of untreated OSA after HGNS activation
Who cannot take part
- Chronic use of opiate medications, illicit drugs, or alcohol dependency
- History of severe excessive daytime sleepiness (Epworth Sleepiness Scale score >16 at time of screening or prior to HGNS), motor vehicle accidents or near-miss incidents due to drowsy driving within the year prior to enrollment
- Significant cardiopulmonary (such as home oxygen requirement), liver, renal, or oncologic disease; neurodegenerative disease; active or recent history of an eating disorder (within the last 5 years)
- Women who are pregnant or planning to become pregnant
- Shift workers, heavy machinery operators, or commercial drivers
- Inability to provide informed consent
Where in United States
- Columbia University Medical CenterNew York, United StatesContact: Jesus LopezTaking people
About the trial
What the trial wants to find out
Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea.
Read full original descriptionShow less
The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).
The 2 groups in the trial
- Therapeutic HGNS (HGNS-on)No study treatment, for comparison
Prior to enrollment in this study, participants will have been implanted with and stabilized on HGNS therapy. As part of clinical care, a therapeutic voltage setting will have been confirmed via overnight sleep study. This arm of the study maintains the participants on the HGNS therapy at the therapeutic voltage they have been using. This is a representation of the patient's baseline status.
- No HGNS therapy (HGNS-off)Other group
HGNS therapy will be turned off by the participant for this arm of the study. This arm will mimic the participant's untreated OSA statement before they had HGNS therapy activated.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA
- Plain-language title
- Effects of pausing nerve stimulation therapy on heart and metabolism in sleep apneaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 July 2025